---
schema_version: "secwatch.filing_event.v1"
accession: "0001477932-23-005506"
form_type: "8-K"
ticker: "BGLC"
cik: "0001737523"
company_name: "BioNexus Gene Lab Corp"
filed_at: "2023-07-24T23:59:59+00:00"
generated_at: "2026-06-13T04:18:52.002475+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# BioNexus closes $5.75M public offering and uplists to Nasdaq

## Summary
- Closed underwritten public offering of 1,437,500 shares at $4.00/share; gross proceeds $5.75M.
- Underwriter fully exercised over-allotment option for 187,500 additional shares.
- Common stock began trading on Nasdaq Capital Market on July 20, 2023 under symbol BGLC.
- Underwriter issued warrants for 115,000 shares at $4.40/share, exercisable for 5 years.
- Lock-up agreements with officers, directors, and certain shareholders for 180 days.

## SEC filing metadata
- accession: 0001477932-23-005506
- form_type: 8-K
- ticker: BGLC
- cik: 0001737523
- company_name: BioNexus Gene Lab Corp
- filed_at: 2023-07-24T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 5.03, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1737523/000147793223005506/0001477932-23-005506-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1737523/000147793223005506/bglc_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001477932-23-005506
- JSON: https://secwatch.observer/filing/0001477932-23-005506.json
- Plain text: https://secwatch.observer/filing/0001477932-23-005506.txt

## Key facts
- Governance Changes
  BioNexus Gene Lab Corp: Increased maximum number of directors from seven to nine (effective 2023-01-01).
  - Change: bylaw amendment
  - Effective: 2023-01-01
  source text: On July 21, 2013, the Board of Directors of the Company approved and ratified the Amended and Restated Bylaws (“Amended Bylaws”) of the Company to increase the maximum number of directors from seven (7) to nine (9), effective as of January 1, 2023.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737523/000147793223005506/0001477932-23-005506-index.htm
- Material Agreements
  BioNexus Gene Lab Corp entered into Underwriting Agreement with Network 1 Financial Securities, Inc. valued at total gross proceeds of $5.75 million (effective 2023-07-20).
  - Action: entry
  - Agreement: underwriting
  - Counterparty: Network 1 Financial Securities, Inc.
  - Value: total gross proceeds of $5.75 million
  - Effective: 2023-07-20
  source text: On July 20, 2023, BioNexus Gene Lab Corp. (the "Company") entered into an underwriting agreement (the "Underwriting Agreement") with Network 1 Financial Securities, Inc., as underwriter (the "Underwriter") pursuant to which the Company agreed to issue and sell, in a firm commitment underwritten public offering by the Company (the “Offering”) of 1,250,000 shares of common stock, priced at a public offering price of $4.00 per share. In addition, pursuant to the Underwriting Agreement, the Underwriter was granted a 45-day option (the “Over-Allotment Option") to purchase up to an additional 187,500 shares of common stock at the public offering price of $4.00 per share. The Underwriter fully exercised the Over-Allotment Option on July 24, 2023. The securities were offered by the Company pursuant to the registration statement on Form S-1 (File No. 333-269753), which was originally filed with the U.S. Securities and Exchange Commission (the “Commission”) under the Securities Act of 1933, as a
  evidence_url: https://www.sec.gov/Archives/edgar/data/1737523/000147793223005506/0001477932-23-005506-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.